JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

JNJ

190.85

-0.66%↓

ABT

126.63

+0.17%↑

MDT

93.85

-0.53%↓

VEEV

293.38

+0.69%↑

A

148.14

+0.67%↑

Search

Guardant Health Inc

Slēgts

SektorsVeselības aprūpe

72.17 4.31

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

69.34

Max

72.53

Galvenie mērījumi

By Trading Economics

Ienākumi

-4.7M

-100M

Pārdošana

29M

232M

Peļņas marža

-43.044

Darbinieki

1,999

EBITDA

22M

-89M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+5.6% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 29. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

3.3B

8.8B

Iepriekšējā atvēršanas cena

67.86

Iepriekšējā slēgšanas cena

72.17

Ziņu noskaņojums

By Acuity

21%

79%

45 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Guardant Health Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 23. okt. 20:49 UTC

Peļņas

Correction to Thermo Fisher Article on Oct. 22

2025. g. 23. okt. 23:51 UTC

Tirgus saruna

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

2025. g. 23. okt. 23:49 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 23. okt. 23:49 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

2025. g. 23. okt. 23:37 UTC

Tirgus saruna

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

2025. g. 23. okt. 22:58 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2025. g. 23. okt. 22:57 UTC

Tirgus saruna

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

2025. g. 23. okt. 22:49 UTC

Iegādes, apvienošanās, pārņemšana

How Trump Sparked a New Era of State Capitalism -2-

2025. g. 23. okt. 22:49 UTC

Iegādes, apvienošanās, pārņemšana

How Trump Sparked a New Era of State Capitalism -- Barrons.com

2025. g. 23. okt. 22:17 UTC

Peļņas

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

2025. g. 23. okt. 21:41 UTC

Peļņas

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

2025. g. 23. okt. 21:05 UTC

Peļņas

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

2025. g. 23. okt. 20:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 23. okt. 20:50 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

2025. g. 23. okt. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 23. okt. 20:35 UTC

Peļņas

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

2025. g. 23. okt. 20:28 UTC

Peļņas

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

2025. g. 23. okt. 20:15 UTC

Tirgus saruna
Peļņas

Global Commodities Roundup: Market Talk

2025. g. 23. okt. 20:10 UTC

Peļņas

Newmont Mining 3Q Adj EPS $1.71

2025. g. 23. okt. 20:10 UTC

Peļņas

Newmont Mining 3Q Sales $5.52B

2025. g. 23. okt. 20:10 UTC

Peļņas

Newmont Mining 3Q EPS $1.67

2025. g. 23. okt. 20:09 UTC

Peļņas

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

2025. g. 23. okt. 20:07 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2025. g. 23. okt. 20:07 UTC

Tirgus saruna
Peļņas

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

2025. g. 23. okt. 20:07 UTC

Peļņas

Blackstone Looks to IPOs for Investment Exits -- Update

2025. g. 23. okt. 20:05 UTC

Peļņas

Intel 3Q Gross Margin 38.2% >INTC

2025. g. 23. okt. 20:04 UTC

Peļņas

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

2025. g. 23. okt. 20:04 UTC

Peļņas

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

2025. g. 23. okt. 20:04 UTC

Peļņas

Intel: 4Q Guidance Excludes Altera >INTC

2025. g. 23. okt. 20:04 UTC

Peļņas

Intel Sees 4Q Adj EPS 8c >INTC

Salīdzinājums

Cenas izmaiņa

Guardant Health Inc Prognoze

Cenas mērķis

By TipRanks

5.6% augšup

Prognoze 12 mēnešiem

Vidējais 71.84 USD  5.6%

Augstākais 90 USD

Zemākais 60 USD

Pamatojoties uz 21 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Guardant Health Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

21 ratings

21

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

38.86 / 47.41Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bullish Evidence

Noskaņojums

By Acuity

45 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat